Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

ClinicalTrials.gov ID: NCT01142401

Public ClinicalTrials.gov record NCT01142401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer

Study identification

NCT ID: NCT01142401
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 118 participants

Conditions and interventions

Conditions

Interventions

Bortezomib Drug
Fulvestrant Drug
Laboratory Biomarker Analysis Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 25, 2010
Primary completion: Jul 29, 2015
Completion: Jan 7, 2021
Last update posted: Nov 26, 2023

2010 – 2021

United States locations

U.S. sites: 21
U.S. states: 6
U.S. cities: 11

Facility	City	State	ZIP	Site status
University of Connecticut	Farmington	Connecticut	06030	—
Yale University	New Haven	Connecticut	06520	—
Cleveland Clinic-Weston	Weston	Florida	33331	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	—
Maimonides Medical Center	Brooklyn	New York	11219	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Mount Sinai Union Square	New York	New York	10003	—
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	New York	10016	—
Mount Sinai West	New York	New York	10019	—
Mount Sinai Saint Luke's	New York	New York	10025	—
Mount Sinai Hospital	New York	New York	10029	—
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York	New York	10032	—
NYP/Weill Cornell Medical Center	New York	New York	10065	—
Montefiore Medical Center-Einstein Campus	The Bronx	New York	10461	—
Montefiore Medical Center-Weiler Hospital	The Bronx	New York	10461	—
Eastchester Center for Cancer Care	The Bronx	New York	10469	—
Case Western Reserve University	Cleveland	Ohio	44106	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center	Cleveland	Ohio	44195	—
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01142401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 26, 2023 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01142401 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →